Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: Results of a phase 1/2 study

Blood

Volumn 118, Issue 4, 2011, Pages 865-873

  Reece, Donna E ^a   Hegenbart, Ute ^b   Sanchorawala, Vaishali ^c   Merlini, Giampaolo ^d   Palladini, Giovanni ^d   Bladé, Joan ^e   Fermand, Jean Paul ^f   Hassoun, Hani ^g   Heffner, Leonard ^h   Vescio, Robert A ⁱ   Liu, Kevin ^j   Enny, Christopher ^j   Esseltine, Dixie Lee ^k   Van De Velde, Helgi ^l   Cakana, Andrew ^j   Comenzo, Raymond L ^m  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PAVIA   (Italy)

^e HOSPITAL CLÍNIC   (Spain)

^f SAINT LOUIS HOSPITAL   (France)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j JOHNSON AND JOHNSON   (United States)

^k MILLENNIUM PHARMACEUTICALS INC   (United States)

^l JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^m TUFTS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CREATININE;

ACUTE HEART FAILURE; ADULT; AGED; AMYLOIDOSIS; ARTICLE; CREATININE CLEARANCE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART VENTRICLE HYPERTROPHY; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN URINE LEVEL; RELAPSE; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 79960934028     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-334227     Document Type: Article

References (50)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337(13):898-909. (Pubitemid 27408573)
2. Comenzo RL. Current and emerging views and treatments of systemic immunoglobulin lightchain (Al) amyloidosis. Contrib Nephrol. 2007;153:195-210. (Pubitemid 44836022)
3. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596. (Pubitemid 36951371)
4. Comenzo RL. Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw. 2007;5(2):179-187. (Pubitemid 46423057)
5. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817-1822.
6. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica. 2007;92(10):1302-1307. (Pubitemid 350144146)
7. Merlini G, Palladini G. Amyloidosis: is a cure possible? Ann Oncol. 2008;19(suppl 4):iv63-iv66.
8. Guidelines Working Group of UK Myeloma Forum, British Committee for Standards in Haematology of the British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004;125(6):681-700.
9. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140(2):85-93.
10. Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica. 2007;92(10):1415- 1418. (Pubitemid 350144161)
11. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083-1093. (Pubitemid 47443213)
12. Cohen AD, Zhou P, Chou J, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol. 2007;139(2):224-233. (Pubitemid 47495869)
13. Gertz MA, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant. 2000;25(5):465-470. (Pubitemid 30137858)
14. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001;28(7):637-642. (Pubitemid 33014596)
15. Dispenzieri A, Lacy M, Zeldenrust SR, et al. Long term follow-up of patients with immunoglobulin light chain amyloidosis treated with lenalidomide and dexamethasone [abstract]. Blood. 2008;112:612a-613a.
16. Kumar S, Hayman SR, Buadi F, et al. A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis [abstract]. Blood. 2009;114:1482a.
17. Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood. 2005;105(7):2949-2951. (Pubitemid 40446290)
18. Palladini G, Russo P, Bragotti LZ, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone (CLD) in previously treated patients with AL amyloidosis [abstract]. Blood. 2009;114:1117a-1118a.
19. Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457-464. (Pubitemid 46105938)
20. Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly-diagnosed AL amyloidosis: a multicenter phase 1/2 dose escalation study. Blood. 2010;116(23):4777-4782.
21. Roussou M, Kastritis E, Gavriatopoulou M, et al. The combination of lenalidomide with low dose dexamethasone and cyclophosphamide is an effective regimen for patients with primary systemic (AL) amyloidosis: results of a phase I/II study. [abstract]. Haematologica. 2010;95:392.
22. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492-496. (Pubitemid 46105943)
23. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071-3076. (Pubitemid 32691956)
24. Richardson PG, Mitsiades C, Schlossman R, et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008;8(7):1053-1072.
25. Richardson PG, Laubach J, Mitsiades C, et al. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010;24(3 suppl 2):22-29.
26. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031-1037.
27. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008;93(2):295-298. (Pubitemid 351397721)
28. Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009;114(8):1489-1497.
29. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487- 2498. (Pubitemid 41007864)
30. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
31. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twiceweekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009;27(30):5023-5030.
32. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895-903.
33. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319-328. (Pubitemid 41098849)
34. Palladini G, Russo P, Foli A, et al. Treatment with oral melphalan and dexamethasone of an extended patient population with AL amyloidosis [abstract]. Blood. 2009;114:1496a.
35. Palladini G, Russo P, Lavatelli F, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol. 2009;88(4):347-350.
36. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936-2938. (Pubitemid 38451663)
37. Brunvand MW, Bitter M. Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant. Haematologica. 2010;95(3):519-521.
38. Singh V, Saad A, Palmer J, Randhawa JK, Hari PN. Response to bortezomib based induction therapy in newly diagnosed light chain (AL) amyloidosis [abstract]. Blood. 2009;114:740a-741a.
39. Gasparetto C, Sanchorawala V, Snyder RM, et al. Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis [abstract]. J Clin Oncol. 2010;28(suppl):579s.
40. Dispenzieri A, Gertz MA, Hayman SR, et al. A pilot study of pomalidomide and dexamethasone in previously treated light chain amyloidosis patients [abstract]. Blood. 2009;114:1482a-1483a.
41. Gibbs SDJ, Gillmore JD, Sattianayagam PT, et al. In AL amyloidosis, both oral melphalan and dexamethasone (Mel-Dex) and risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) have similar efficacy as upfront treatment [abstract]. Blood. 2009;114:310a.
42. Gillmore J, Cocks K, Gibbs SDJ, et al. Cyclophosphamide, thalidomide and dexamethasone (CTD) versus melphalan plus dexamethasone (MD) for newly-diagnosed systemic AL amyloidosis: results from the UK Amyloidosis Treatment Trial [abstract]. Blood. 2009;114:1120a.
43. Dhodapkar MV, Hussein MA, Rasmussen E, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood. 2004;104(12):3520-3526. (Pubitemid 39564422)
44. Palladini G, Anesi E, Perfetti V, et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol. 2001;113(4):1044-1046. (Pubitemid 32634774)
45. Dispenzieri A, Kyle RA. Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol. 2005;18(4):673-688. (Pubitemid 40984121)
46. Charaf E, Iskandar SB, Blevins A, bi-Saleh B, Fahrig S. Cardiac amyloidosis responding to bortezomib: case report and review of literature. Curr Cardiol Rev. 2009;5(3):228-236.
47. Tamaki H, Naito Y, Lee-Kawabata M, et al. Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib. Int J Hematol. 2010;92(4):655-658.
48. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology Multiple Myeloma (Version 1.2011), December 2010. http://www.nccn.org/professionals/physician-gls/PDF/myeloma.pdf. Accessed April 7, 2011.
49. Landau H, Hassoun H, Rosenzweig MA, et al. Maintained hematologic and organ responses at two years following stem cell transplant in systemic light-chain amyloidosis (AL) using shortcourse bortezomib and dexamethasone consolidation therapy. Blood. 2010;116(21):991a.
50. Sanchorawala V, Yanarella L, Quillen K, et al. Bortezomib and high dose melphalan followed by autologous stem cell transplantation (BortHDM/SCT) for the treatment of AL amyloidosis: results of a feasibility study [abstract]. Blood. 2009;114:4353.